Clinical Trials · NCT00250796
Trial of Thalidomide, a- Interferon +/- Octreotide in Patients With Unresectable Hepatocellular Carcinoma
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- University of New Mexico
- Enrollment
- 12
- Start date
- Sep 2000
- Locations
- 2 sites, United States
- Primary endpoint
- Determine the response rate and time to progression of the combination of thalidomide, interferon, and octreotide in patients with unresectable hepatocellular carcinoma.